Aurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised
New Delhi: Aurobindo Pharma has clarified that reports of its potential acquisition of Prague-based generic drugmaker Zentiva are premature, stating that no binding agreement has been finalized.
In a regulatory filing on August 20, 2025, the company said it “regularly explores various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value.” However, it emphasized that “no binding agreement or definitive decision has been made by the Board of Directors of the Company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon.”
Earlier, reports in The Economic Times suggested that Aurobindo Pharma was the frontrunner to acquire Zentiva from Advent International in a deal valued at USD 5–5.5 billion (Rs 43,500–47,900 crore). If completed at these valuations, the deal would become the largest-ever overseas acquisition by an Indian pharmaceutical company, surpassing Sun Pharma’s acquisition of Ranbaxy and Biocon Biologics’ acquisition of Viatris.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.